Nosanchuk Joshua D, Zancopé-Oliveira Rosely M, Hamilton Andrew J, Guimarães Allan J
Department of Medicine, Albert Einstein College of Medicine Bronx, NY, USA.
Front Microbiol. 2012 Feb 2;3:21. doi: 10.3389/fmicb.2012.00021. eCollection 2012.
The endemic human pathogenic fungus Histoplasma capsulatum is a major fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10 years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.
地方性人类致病真菌荚膜组织胞浆菌是一种主要的真菌病原体，临床表现多种多样，从轻度局灶性肺部疾病到危及生命的全身感染。尽管唑类药物（如伊曲康唑和伏立康唑）以及两性霉素B对荚膜组织胞浆菌具有显著活性，但因组织胞浆菌病住院的患者中约有十分之一死亡。因此，正在寻求治疗该疾病的新方法。在过去10年中，研究表明单克隆抗体（mAb）可以改变组织胞浆菌病的发病机制。已证明靶向真菌细胞表面蛋白或宿主共刺激分子的单克隆抗体对疾病有影响。本综述将详细阐述我们目前关于抗体治疗对组织胞浆菌病影响的知识。
